{"title":"Clinicopathological and prognostic features of pancreatic acinar cell carcinoma: a nationwide multicenter study in Japan.","authors":"Atsushi Kanno, Noriyoshi Fukushima, Naohiro Sata, Kenji Notohara, Masamichi Hayashi, Takaaki Furukawa, Ryota Higuchi, Kosuke Okuwaki, Masayuki Ohtsuka, Toru Watanabe, Kazuhiko Shioji, Toshiya Abe, Hirohisa Kitagawa, Ryuta Muraki, Daisuke Hashimoto, Tomoyuki Satake, Junpei Yamaguchi, Namikatsu Takahara, Jun Nakahodo, Hiroaki Yasuda, Kazuichi Okazaki, Yoshifumi Takeyama, Hiroki Yamaue, Sohei Satoi, Atsushi Masamune","doi":"10.1007/s00535-026-02540-z","DOIUrl":"https://doi.org/10.1007/s00535-026-02540-z","url":null,"abstract":"<p><strong>Background: </strong>To characterize the clinicopathological features of pancreatic acinar cell carcinoma (PACC) nationwide, we conducted a multicenter study in Japan.</p><p><strong>Methods: </strong>The clinical data from 387 patients with pathologically diagnosed PACC treated between 2000 and 2022 were collected from 85 Japanese tertiary referral centers. Additionally, 108 pathological specimens from 41 institutions underwent centralized pathological evaluation using hematoxylin and eosin staining, immunohistochemistry, and Ki-67 labeling. The associations between clinicopathological factors and overall survival (OS) were analyzed using Cox proportional hazards models.</p><p><strong>Results: </strong>Among the 387 patients, 276 (71.3%) were male, with a median age of 64 years (interquartile range, 55-72 years). The surgical resection was performed in 260 patients, whereas 127 had non-resectable disease. The median survival time and 5-year survival rate were 2610 days and 55.3%, respectively, among patients who underwent resection, compared with 415 days and 4.5%, respectively, among those who did not (p < 0.001). Older age, non-resection, and advanced stage were independently associated with shorter OS. In the resection cohort, total pancreatectomy and disease recurrence were associated with lower OS. In the non-resection cohort, the absence of chemotherapy was associated with worse prognosis, whereas absence of symptoms and treatment with FOLFIRINOX were associated with longer OS. In the pathological analysis, Stage IIb/IV disease, alpha-fetoprotein-positive immunostaining, and Ki-67 ≥ 30% were independent prognostic factors associated with lower OS.</p><p><strong>Conclusions: </strong>This nationwide multicenter study characterized the clinicopathological features of PACC and identified prognostic factors for OS. These findings may contribute to improved diagnostic and treatment strategies for this rare malignancy.</p>","PeriodicalId":16059,"journal":{"name":"Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149407177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Annualized fibrosis dynamics in metabolic dysfunction-associated steatotic liver disease: a paired-biopsy cohort.","authors":"Miwa Kawanaka, Kazuya Miyamoto, Shiho Murakami, Jinpeng Li, Ying Liu, Emi Tanaka, Nozomi Miyake, Takuya Adachi, Yasuto Takeuchi, Hideki Onishi, Ken Nishino, Takashi Fushimi, Noriyo Urata, Hirofumi Kawamoto, Motoyuki Otsuka","doi":"10.1007/s00535-026-02525-y","DOIUrl":"https://doi.org/10.1007/s00535-026-02525-y","url":null,"abstract":"<p><strong>Background: </strong>Fibrosis stage is the strongest histologic determinant of outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD), but annualized fibrosis dynamics under routine care remain insufficiently quantified. We characterized fibrosis progression rate (FPR) in a long-term, pre-incretin paired-biopsy cohort to provide reference data for emerging metabolic therapies.</p><p><strong>Methods: </strong>We analyzed 153 patients with MASLD who underwent repeat liver biopsy at a single center over a median interval of 5.9 years (range, 0.5-24). No patient received a GLP-1 receptor agonist or a dual GLP-1/GIP receptor agonist during follow-up. FPR was defined as the annualized change in fibrosis stage (stage/year). Factors associated with fibrosis improvement were examined using multivariable logistic regression.</p><p><strong>Results: </strong>Fibrosis improved in 38 patients (25%), remained stable in 66 (43%), and progressed in 49 (32%). FPR varied substantially among patients with improvement or progression, revealing bidirectional and heterogeneous fibrosis dynamics not captured by categorical staging alone. FPR shifted in parallel with MASLD activity score change and was more closely related to changes in hepatocellular ballooning and lobular inflammation than to steatosis. Male sex, advanced baseline fibrosis, and ≥5% body weight reduction were associated with fibrosis improvement, with the likelihood increasing as these factors accumulated.</p><p><strong>Conclusion: </strong>In this real-world pre-incretin paired-biopsy cohort, fibrosis change under routine care was bidirectional and heterogeneous, with wide variation in annualized rate. These data provide a reference for evaluating how emerging metabolic therapies modify the longitudinal course of MASLD.</p>","PeriodicalId":16059,"journal":{"name":"Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149342470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Silvia Camera, Margherita Rimini, Masafumi Ikeda, Oluseyi Abidoye, Jessica Lucchetti, Lorenzo Antonuzzo, Jin Won Kim, Federico Nichetti, Anna Saborowski, Christoph Gerdes, Tiziana Pressiani, Caterina Vivaldi, Ilario Giovanni Rapposelli, Frederik Peeters, Chiara Braconi, David J Pinato, Emiliano Tamburini, Chiara Pircher, Luisa Foltran, Stefano Tamberi, Florian Castet, Monica Verrico, Alessandro Parisi, Nuno Couto, Hong Jae Chon, Andrea Martirena, Angela Lamarca, Matteo Landriscina, Fabian Finkelmeier, Ester Oneda, Antonio Avallone, Emanuela Dell'Aquila, Lukas Perkhofer, Il Hwan Kim, Vincenzo Formica, Cidalia Maria de Sousa Pinto, Ingrid Garajova, Beodeul Kang, Salvatore Corallo, Elisabetta Fenocchio, Giovanni Farinea, Alessandro Pastorino, Anna Diana, Changhoon Yoo, Marta Schirripa, Maria Grazia Rodriquenz, Mario Scartozzi, Lucrezia Zumstein, Michele Ghidini, Gerald W Prager, Giuseppe Aprile, Gian Paolo Spinelli, Su Yung-Yeh, Stephen L Chan, Emily Warmington, Alessia Lancianese, Tomoyuki Satake, Tanios Bekaii-Saab, Guido Giordano, Daniele Lavacchi, Laura Passeri, Michele Ferrara, Federico Rossari, Federica Lo Prinzi, Minsu Kang, Alessandra Anna Prete, Silvia Bozzarelli, Mara Persano, Lorenzo Fornaro, Rita Balsano, Monica Niger, Sara Lonardi, Francesca Salani, Arndt Vogel, Gianluca Masi, Lorenza Rimassa, Andrea Casadei-Gardini
{"title":"From trial efficacy to real-world effectiveness: evaluating the generalizability of cisplatin-gemcitabine-durvalumab in advanced biliary tract cancers.","authors":"Silvia Camera, Margherita Rimini, Masafumi Ikeda, Oluseyi Abidoye, Jessica Lucchetti, Lorenzo Antonuzzo, Jin Won Kim, Federico Nichetti, Anna Saborowski, Christoph Gerdes, Tiziana Pressiani, Caterina Vivaldi, Ilario Giovanni Rapposelli, Frederik Peeters, Chiara Braconi, David J Pinato, Emiliano Tamburini, Chiara Pircher, Luisa Foltran, Stefano Tamberi, Florian Castet, Monica Verrico, Alessandro Parisi, Nuno Couto, Hong Jae Chon, Andrea Martirena, Angela Lamarca, Matteo Landriscina, Fabian Finkelmeier, Ester Oneda, Antonio Avallone, Emanuela Dell'Aquila, Lukas Perkhofer, Il Hwan Kim, Vincenzo Formica, Cidalia Maria de Sousa Pinto, Ingrid Garajova, Beodeul Kang, Salvatore Corallo, Elisabetta Fenocchio, Giovanni Farinea, Alessandro Pastorino, Anna Diana, Changhoon Yoo, Marta Schirripa, Maria Grazia Rodriquenz, Mario Scartozzi, Lucrezia Zumstein, Michele Ghidini, Gerald W Prager, Giuseppe Aprile, Gian Paolo Spinelli, Su Yung-Yeh, Stephen L Chan, Emily Warmington, Alessia Lancianese, Tomoyuki Satake, Tanios Bekaii-Saab, Guido Giordano, Daniele Lavacchi, Laura Passeri, Michele Ferrara, Federico Rossari, Federica Lo Prinzi, Minsu Kang, Alessandra Anna Prete, Silvia Bozzarelli, Mara Persano, Lorenzo Fornaro, Rita Balsano, Monica Niger, Sara Lonardi, Francesca Salani, Arndt Vogel, Gianluca Masi, Lorenza Rimassa, Andrea Casadei-Gardini","doi":"10.1007/s00535-026-02535-w","DOIUrl":"https://doi.org/10.1007/s00535-026-02535-w","url":null,"abstract":"<p><strong>Background: </strong>Cisplatin-gemcitabine-durvalumab (CGD) has established a new first-line standard in advanced biliary tract cancers (BTC). However, the extent to which trial results translate into real-world populations remains uncertain. We assessed whether the survival outcomes observed in the TOPAZ-1 CGD arm were reproduced in a cohort of patients with advanced BTC treated with CGD in routine clinical practice.</p><p><strong>Methods: </strong>We conducted a retrospective, international, multicenter, real-world study including patients treated with CGD across 55 centers in 12 countries. Reconstructed individual patient-level data from TOPAZ-1 were used as comparator. Real-world patients were classified as TOPAZ-1-in or TOPAZ-1-out according to trial eligibility criteria. Entropy balancing aligned baseline characteristics between cohorts. Overall survival (OS) was compared using weighted pooled survival models and restricted mean survival time (RMST) analyses.</p><p><strong>Results: </strong>Overall, 1382 real-world patients were included in the primary OS analysis. TOPAZ-1 eligibility status was evaluable in 1358 patients (912 TOPAZ-1-in and 446 TOPAZ-1-out); eligibility-stratified survival analyses included 1,351 patients with complete required data (910 TOPAZ-1-in and 441 TOPAZ-1-out). After calibration, baseline characteristics were well balanced. OS was longer in the real-world cohort than in TOPAZ-1 in unweighted (HR 0.83, p = 0.012) and calibrated analyses (HR 0.84, p = 0.018). TOPAZ-1-in patients had longer observed OS than the trial population (HR 0.76, p < 0.001), whereas TOPAZ-1-out patients had similar observed outcomes (HR 0.98, p = 0.85), with consistent calibrated results. Exploratory subgroup analyses showed the largest observed OS differences for ECOG PS 0 (calibrated HR 0.61, p < 0.001) and locally advanced disease (calibrated HR 0.38, p < 0.001); RMST analyses showed increasing absolute between-cohort survival differences over time.</p><p><strong>Conclusion: </strong>The survival outcomes observed in the TOPAZ-1 CGD arm were broadly reproduced in this large real-world cohort. Findings for ECOG PS 0 and locally advanced disease are exploratory and should be interpreted cautiously because of reduced effective sample size and limited empirical overlap.</p>","PeriodicalId":16059,"journal":{"name":"Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149334177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Salvage esophagectomy versus photodynamic therapy for localized residual or recurrent esophageal squamous cell carcinoma after definitive chemoradiotherapy or radiotherapy: a single-center comparative study.","authors":"Naoto Ujiie, Chiaki Sato, Yusuke Taniyama, Hiroshi Okamoto, Yohei Ozawa, Hirotaka Ishida, Michiaki Unno, Takashi Kamei","doi":"10.1007/s00535-026-02533-y","DOIUrl":"https://doi.org/10.1007/s00535-026-02533-y","url":null,"abstract":"<p><strong>Background: </strong>Salvage esophagectomy is considered the standard curative treatment for localized residual or recurrent esophageal cancer after definitive chemoradiotherapy (CRT), but it is associated with substantial morbidity. Photodynamic therapy (PDT) has emerged as a less invasive alternative. We compared the outcomes of salvage esophagectomy and PDT for localized residual or recurrent esophageal squamous cell carcinoma (ESCC) after definitive CRT or radiotherapy (RT).</p><p><strong>Methods: </strong>We retrospectively reviewed 91 patients with cT1-2N0M0 residual or recurrent ESCC after definitive CRT or RT who underwent salvage esophagectomy (n = 33) or PDT (n = 58) at a single institution. Overall survival (OS), disease-specific survival (DSS), and treatment-related outcomes were evaluated.</p><p><strong>Results: </strong>Patients treated with PDT were significantly older and had a higher comorbidity burden than those undergoing salvage esophagectomy. Salvage esophagectomy achieved an R0 resection rate of 94.0% but was associated with severe postoperative complications in 48.5% of patients, including one treatment-related death. In the PDT group, initial local complete response was achieved in 74.1% of patients, with one grade 3 adverse event and no treatment-related mortality. No significant differences were observed between the groups in OS (p = 0.597) or DSS (p = 0.670).</p><p><strong>Conclusions: </strong>This study does not establish equivalence or non-inferiority between PDT and salvage esophagectomy. PDT demonstrated a favorable safety profile and may offer an organ-preserving salvage treatment option for carefully selected patients with localized residual or recurrent ESCC after definitive CRT or RT, particularly those unsuitable for surgery because of advanced age, substantial comorbidities, or limited surgical tolerance.</p>","PeriodicalId":16059,"journal":{"name":"Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149321990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rong Yan, Armand Ghozati, Haiming Chen, Kalyan Kumar Pasunooti, Waliul Islam, Ling Li, Florin M Selaru
{"title":"Modeling intestinal fibrosis in inflammatory bowel disease: translational animal models and ex vivo platforms.","authors":"Rong Yan, Armand Ghozati, Haiming Chen, Kalyan Kumar Pasunooti, Waliul Islam, Ling Li, Florin M Selaru","doi":"10.1007/s00535-026-02527-w","DOIUrl":"https://doi.org/10.1007/s00535-026-02527-w","url":null,"abstract":"<p><p>Intestinal fibrosis is a common and debilitating complication of inflammatory bowel disease (IBD), particularly Crohn's disease (CD). Fibrotic remodeling can also occur in ulcerative colitis (UC). Despite its clinical significance, there are currently no approved antifibrotic therapies, largely due to an incomplete understanding of the fibrogenic mechanisms and a lack of effective translational models. In this review, we examine several categories of animal models, including chemical-induced, microbial/biologic, immune cell-mediated, mechanical damage repair, genetically susceptible and cytokine-driven, and innovative models such as radiation-induced and organoid models. We evaluate the utility of these models in recapitulating key features of fibrotic IBD, including ECM remodeling, fibroblast activation, chronic inflammation, tissue stiffening, muscularis propria remodeling, and-in selected systems-fixed luminal narrowing/stricture. By outlining the advantages and limitations of each model, we aim to provide researchers with a practical, application-oriented framework that links each model to its optimal research use, thereby supporting the development of targeted, pathophysiologically-driven therapeutic strategies for IBD-associated fibrosis and fibrostenosis.</p>","PeriodicalId":16059,"journal":{"name":"Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149321989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"From IBS to IBD? Strengthening causal inference and clinical translation in Song et al.","authors":"Mulavagili Vijayasimha","doi":"10.1007/s00535-026-02400-w","DOIUrl":"10.1007/s00535-026-02400-w","url":null,"abstract":"","PeriodicalId":16059,"journal":{"name":"Journal of Gastroenterology","volume":" ","pages":"1678-1679"},"PeriodicalIF":5.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147485707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Enhanced COMP expression induced by Helicobacter pylori drives gastric cancer progression by NOTCH2/SMAD3 pathway.","authors":"Zhaotian Feng, Muhua Luan, Wenshuai Zhu, He Qi, Yuanxin Xing, Xiaoli Ma, Yunshan Wang, Yanfei Jia","doi":"10.1007/s00535-026-02462-w","DOIUrl":"10.1007/s00535-026-02462-w","url":null,"abstract":"<p><strong>Background: </strong>The main risk factor for gastric carcinogenesis is infection with Helicobacter pylori (H. pylori) that injects the bacterial oncoprotein cytotoxin-associated gene A (CagA). Aberrant cartilage oligomeric protein (COMP) expression is implicated in tumorigenesis and cancer development. However, the critical mediators participating in regulation of COMP and how COMP contributes to the progression of gastric cancer (GC) have not been elucidated.</p><p><strong>Methods: </strong>To evaluate H. pylori-mediated transcriptional changes, RNA-seq was performed. The clinical relevance and prognostic potential of COMP in GC were examined via Western blot and IHC assays. Functional roles of COMP were further probed using in vitro cellular models and in vivo animal studies. Putative mechanistic networks were elucidated through chromatin immunoprecipitation (ChIP) and co-immunoprecipitation (Co-IP) experiments.</p><p><strong>Results: </strong>In GC cell lines and mouse models, both H. pylori colonization and its virulence factor CagA upregulated COMP at transcriptional and translational levels. COMP expression is markedly elevated in H. pylori-related GC and is associated with poor prognosis. The inhibition of COMP curtailed the pro-proliferative, metastatic, and epithelial-mesenchymal transition (EMT) capacities of the CagA in GC cells. H. pylori infection enhances COMP expression via the activation of KLF5. COMP binding to NOTCH2 and JAG1 facilitates the interaction between NOTCH2 and JAG1, hence activating downstream SMAD3, which promotes EMT in GC.</p><p><strong>Conclusions: </strong>H. pylori infection depends on CagA/KLF5 to induce COMP expression and highlights the COMP/NOTCH2/SMAD3/EMT axis in modulating GC progression, which may reveal actionable targets for GC therapy.</p>","PeriodicalId":16059,"journal":{"name":"Journal of Gastroenterology","volume":" ","pages":"1548-1562"},"PeriodicalIF":5.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148387645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yuan Xia, Yu Liu, Ai Peng, Yating Su, Rongyin Sun, Masota Tanaka, Chunhong Qiu
{"title":"Stage-associated remodeling of CD169 macrophage states is linked to immune regulation in colitis-associated colorectal cancer.","authors":"Yuan Xia, Yu Liu, Ai Peng, Yating Su, Rongyin Sun, Masota Tanaka, Chunhong Qiu","doi":"10.1007/s00535-026-02463-9","DOIUrl":"10.1007/s00535-026-02463-9","url":null,"abstract":"<p><strong>Background: </strong>Colitis-associated colorectal cancer (CAC) is driven by chronic inflammation and immune dysregulation. However, how macrophage state heterogeneity is organized across different stages of CAC progression remains unclear.</p><p><strong>Methods: </strong>Here, using genetic depletion, single-cell transcriptomics, and pharmacological intervention, and analysis of human colitis-associated colorectal cancer specimens, we identify stage-associated remodeling of CD169-associated macrophage states during CAC progression.</p><p><strong>Results: </strong>We demonstrate that CD169 marks functionally distinct macrophage states with opposing roles: CD169-low macrophages predominate during colitis and exhibit pro-inflammatory features, whereas CD169-mid/high macrophages emerge at tumor stages, localize preferentially to para-tumor regions, and display immunosuppressive and immune-inert interaction profiles. These observations support stage-associated remodeling of CD169-associated macrophage states during CAC progression. Importantly, CD169 depletion restrains tumor growth and enhances intratumoral T cell infiltration, highlighting CD169-associated macrophages as potential therapeutic targets in inflammation-driven colorectal tumorigenesis.</p><p><strong>Conclusions: </strong>Together, our findings reveal stage-associated remodeling of CD169-associated macrophage states during CAC progression, with distinct CD169 states exhibiting divergent immune regulatory features at different disease stages. These findings highlight the importance of considering macrophage state heterogeneity when targeting CD169-associated pathways and support further investigation of state-informed therapeutic strategies in inflammation-driven colorectal tumorigenesis.</p>","PeriodicalId":16059,"journal":{"name":"Journal of Gastroenterology","volume":" ","pages":"1563-1581"},"PeriodicalIF":5.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13695605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148317598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}